EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Second-generation antipsychotics and metabolic syndrome: a role for mitochondria

Katherine R H Mortimer, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti

Frontiers in Psychiatry · 24.11.2023 · 14

DOI: 10.3389/fpsyt.2023.1257460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 24.11.2023. Verfasst von Katherine R H Mortimer und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even greater in patients who are taking second-generation antipsychotics (SGAs). SGAs exacerbate metabolic abnormalities and lead to a 3-fold increased risk of severe weight gain, type 2 diabetes, and cardiovascular disease in patients. Mitochondrial dysfunction is a hallmark of MetS. Mitochondria process glucose and fatty acids into ATP. If these processes are impaired, it can result in dyslipidaemia, hyperglycaemia and an imbalance between nutrient input and energy output. This leads to increased adiposity, insulin resistance and atherosclerosis. It is unclear how SGAs induce MetS and how mitochondria might be involved in this process. It has been found that SGAs impair cellular glucose uptake in liver, dysregulating glucose and fatty acid metabolism which leads to an accumulation of glucose and/or lipids and an increase reactive oxygen species (ROS) which target mitochondrial proteins. This affects complexes of the electron transport chain (ETC) to reduce mitochondrial respiration. While there is a suggestion that SGAs may interact with a variety of processes that disrupt mitochondrial function, some of the results are conflicting, and a clear picture of how SGAs interact with mitochondria in different cell types has not yet emerged. Here, we outline the current evidence showing how SGAs may trigger mitochondrial dysfunction and lead to the development of MetS.

Schlagwörter

Stichwörter der Autor:innen

antipsychoticsenergy metabolismmetabolic syndromemitochondriapsychosis

Autor:innen und Institutionen

  • School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom.
  • Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom.

Zitieren

APA

Mortimer, K. R. H., Katshu, M. Z. U. H., & Chakrabarti, L. (2023). Second-generation antipsychotics and metabolic syndrome: a role for mitochondria. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1257460

Vancouver

Mortimer KRH, Katshu MZUH, Chakrabarti L. Second-generation antipsychotics and metabolic syndrome: a role for mitochondria. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1257460

BibTeX
@article{Mortimer2023,
  author = {Mortimer, Katherine R H and Katshu, Mohammed Zia Ul Haq and Chakrabarti, Lisa},
  title = {Second-generation antipsychotics and metabolic syndrome: a role for mitochondria},
  journal = {Frontiers in Psychiatry},
  year = {2023},
  volume = {14},
  doi = {10.3389/fpsyt.2023.1257460}
}
Kostenlos starten →